Randox Presents Acusera Smart Controls Range

With approximately 70% of clinical decisions based on laboratory test results, the results provided must be accurate and reliable to prevent potential misdiagnosis or inappropriate treatment. Randox offers high-quality material that can help streamline procedures, whilst saving time and money for laboratories of all sizes and budgets. Randox offers an extensive product offering comprising third-party QCs & calibrators, interlaboratory data management, external quality assessment, calibration verification, and molecular IQC and EQA for infectious disease testing. Specializing in consolidation, the Acusera range of multi-analyte controls is designed to reduce the number of individual controls required to cover a lab’s test menu, ultimately reducing costs, preparation time, and storage space.

At the 2025 edition of Medlab Middle East, Randox is highlighting its Acusera Smart controls range that is designed to fit directly onto a wide range of test systems without the need to aliquot material, thereby streamlining the QC process by minimizing human error and optimizing workflow. The Acusera Smart Controls range comprises controls for clinical chemistry, immunoassay, liquid cardiac, and PTH. The Acusera Smart PTH Control is intended for use with IVD assays for the quantitative determination of Parathyroid Hormone in human serum and plasma. The Acusera Smart Liquid Cardiac Control is designed to cover a range of cardiac markers at clinical decision levels, eliminating the need for additional low-level controls at extra expenses. It is intended for use with IVD assays for the quantitative determination of 7 cardiac markers. The Acusera Smart Liquid Chemistry Control is intended for IVD use in the QC of diagnostic assays. Three clinically significant levels are available. Covering 98 analytes, the control enables effective consolidation and cost savings. The Acusera Smart Liquid Immunoassay Control is intended for IVD use to cover immunoassay testing in a single tube. The three clinically significant levels provided not only ensure accurate performance at key decision levels but also eliminate the need for additional controls, enabling greater consolidation and cost savings.